INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01801 INNOVENT BIO

Trading 02-03 14:57:03

79.200

+0.500

+0.64%

High79.400	Low77.150	Vol5.28M
Open78.700	D1 Closing78.700	Amplitude2.86%
Mkt Cap137.41B	Tradable Cap137.41B	Total Shares1.74B
T/O413.54M	T/O Rate0.30%	Tradable Shares1.74B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"INNOVENT BIO","latestPrice":79.2,"timestamp":1770101798890,"preClose":78.7,"halted":0,"volume":5279909,"delay":0,"changeRate":0.0063532401524777635,"floatShares":1735000000,"shares":1735000000,"eps":-0.06548800849966797,"marketStatus":"Trading","change":0.5,"latestTime":"02-03 14:57:03","open":78.7,"high":79.4,"low":77.15,"amount":413538340,"amplitude":0.02859,"askPrice":79.2,"askSize":20000,"bidPrice":79.1,"bidSize":17000,"shortable":3,"etf":0,"ttmEps":0.7598528147494238,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770106200000},"marketStatusCode":2,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":78.7,"openAndCloseTimeList":[[1770082200000,1770091200000],[1770094800000,1770105600000]],"volumeRatio":0.747498,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.4735,"impliedVolPercentile":0.1526},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2607001590","title":"Novo Nordisk's China President Zhou to step down in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2607001590","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607001590?lang=en_us&edition=fundamental","pubTime":"2026-01-30 17:46","pubTimestamp":1769766370,"startTime":"0","endTime":"0","summary":"UPDATE 1-Novo Nordisk's China President Zhou to step down in MarchUpdates with context about Novo's China competition. BEIJING, Jan 30  - The longtime head of Novo Nordisk's NOVOb.CO China business will leave the company, the Danish drugmaker said on Friday, as it competes against Eli Lilly LLY.N and a growing number of local drugmakers in the world's second largest pharmaceutical market.Christine Zhou, a senior vice president who has led the firm's operations in Taiwan, Hong Kong, Macau, and mainland China since 2018, will leave at the end of March, Novo said in a statement on its official WeChat account.Zhou was in charge for rollouts of both its blockbuster diabetes drug Ozempic, approved in China in 2021, and later the obesity drug Wegovy. Novo has since faced off against emerging rivals in diabetes and obesity, including drugs from Lilly and Chinese drugmaker Innovent Biologics 1801.HK.Earlier on Friday, another drugmaker, China's Sciwind Biosciences, said its own type 2 diabetes ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nL6N3YV0I7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","HK0000165453.HKD","LU2097828805.USD","BK1161","LU1969619763.USD","LU0502904849.HKD","BK1589","LU2097828557.USD","LU2097828631.EUR","01801","LU2242644610.SGD","LU0455707207.USD","LU2097828714.EUR","BK1583","LU2488822045.USD","LU2097828474.EUR"],"gpt_icon":0},{"id":"1111326310","title":"Valuation Ranges of Biopharma: Insights from Innovent Biologics, Hengrui Pharmaceuticals, and BeiGene","url":"https://stock-news.laohu8.com/highlight/detail?id=1111326310","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111326310?lang=en_us&edition=fundamental","pubTime":"2026-01-30 17:06","pubTimestamp":1769763994,"startTime":"0","endTime":"0","summary":"Evaluating Biopharma stocks requires looking beyond traditional metrics, focusing instead on companies that have successfully navigated the entire drug development lifecycle—from molecule discovery...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1781817850.SGD","LU2097828714.EUR","LU1303224171.USD","LU1997245094.SGD","LU2580892789.USD","BK0239","LU2097828557.USD","BK1589","BK4585","LU0359201612.USD","LU1023057109.AUD","BK1191","BK1588","01276","LU2242644610.SGD","LU1997245177.USD","LU0359202008.SGD","LU2097828631.EUR","LU1146622755.USD","01801","LU0588546209.SGD","LU1719994722.HKD","LU2495084118.USD","LU1255011170.USD","LU2097828474.EUR","688235","BK1583","06160","LU1064130708.USD","LU1820825898.SGD","LU0502904849.HKD","LU0455707207.USD","LU2097828805.USD","LU2148510915.USD","LU1997244956.HKD","BK0183","BK1161","LU1580142542.USD","LU0359201885.HKD","LU1328615791.USD","BK4139","600276","LU1251922891.USD","BK0196","LU2488822045.USD","LU1655091616.SGD","LU1969619763.USD","LU2328871848.SGD","LU0405327494.USD","HK0000165453.HKD","BK0028","BK4526","BK0012","BK0060","BK1500","LU2543165471.USD","LU2580892862.HKD","LU2289578879.USD","LU1064131003.USD","LU0405327148.USD","BK0188","LU0307460666.USD","ONC","LU1770034418.SGD"],"gpt_icon":0},{"id":"1128000326","title":"Hong Kong Stock Movement | Innovent Biologics (01801) Rises Nearly 3% as IBI3003 Receives FDA Fast Track Designation for Multiple Myeloma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1128000326","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128000326?lang=en_us&edition=fundamental","pubTime":"2026-01-28 10:18","pubTimestamp":1769566699,"startTime":"0","endTime":"0","summary":"Innovent Biologics (01801) saw its shares climb nearly 3%, reaching an increase of 2.2% to HK$83.6 by the time of writing, with a trading volume of HK$204 million. According to an announcement on the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","HK0000165453.HKD","LU0502904849.HKD","LU2097828805.USD","BK1583","LU2097828714.EUR","LU2242644610.SGD","LU2328871848.SGD","01801","BK1161","LU2488822045.USD","LU1969619763.USD","LU2097828474.EUR","LU2097828631.EUR","LU0455707207.USD","LU2097828557.USD"],"gpt_icon":0},{"id":"2606069222","title":"FDA Grants Fast Track Designation to Innovent's IBI3003 for Relapsed or Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2606069222","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606069222?lang=en_us&edition=fundamental","pubTime":"2026-01-27 08:00","pubTimestamp":1769472021,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. announced that its anti-GPRC5D/BCMA/CD3 trispecific antibody, IBI3003, has received Fast Track Designation from the U.S. Food and Drug Administration  for the treatment of relapsed or refractory multiple myeloma in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. The designation is intended to facilitate the development and expedite the review of IBI3003, which is currently undergoing Phase 1/2 clinical trials in China and Australia, with plans to initiate similar trials in the United States.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL5fvCDY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01911","LU2097828805.USD","LU2328871848.SGD","BK1161","LU2488822045.USD","LU2097828557.USD","BK1583","LU0502904849.HKD","LU1969619763.USD","BK1589","LU2097828631.EUR","LU2097828714.EUR","LU0455707207.USD","LU2242644610.SGD","01801","HK0000165453.HKD","BK1147","LU2097828474.EUR"],"gpt_icon":0},{"id":"2606222052","title":"Innovent Announces Ibi3003 (Gprc5d/Bcma/Cd3 Trispecific Antibody) Receives Fast Track Designation From the U.S. FDA for Relapsed or Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2606222052","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606222052?lang=en_us&edition=fundamental","pubTime":"2026-01-27 08:00","pubTimestamp":1769472000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA390P39:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1589","LU0455707207.USD","LU2097828631.EUR","BK1583","LU2242644610.SGD","LU2097828557.USD","LU2488822045.USD","LU2097828474.EUR","BK1161","LU2328871848.SGD","LU1969619763.USD","LU2097828805.USD","LU0502904849.HKD","HK0000165453.HKD","01801","LU2097828714.EUR"],"gpt_icon":0},{"id":"2602311894","title":"Innovent Biologics Reports Positive Phase 1b Results for IBI324 in Eye Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2602311894","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602311894?lang=en_us&edition=fundamental","pubTime":"2026-01-09 08:00","pubTimestamp":1767916821,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc., in collaboration with its partner Ollin Biosciences, has announced positive topline results from the randomized, head-to-head Phase 1b JADE clinical study. The study compared IBI324 , a next-generation VEGF/Ang2 bispecific antibody, to faricimab  in over 160 patients with diabetic macular edema  or wet age-related macular degeneration . According to the announcement, OLN324 demonstrated superior outcomes and is characterized by higher anti-Ang2 potency and a differentiated profile for first-line standard of care. Full results from the JADE study are scheduled to be presented at the Angiogenesis, Exudation, and Degeneration 2026 symposium on February 7, 2026. Innovent and Ollin plan to advance OLN324 into global Phase 3 studies for both DME and wAMD.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL1BjwzH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","LU2097828714.EUR","LU2328871848.SGD","BK1583","LU2242644610.SGD","HK0000165453.HKD","01911","LU0455707207.USD","BK1589","BK1161","LU2097828631.EUR","LU1969619763.USD","BK1147","LU2097828557.USD","LU2097828805.USD","LU2488822045.USD","LU0502904849.HKD","01801"],"gpt_icon":0},{"id":"2602059319","title":"Innovent's Partner Ollin Biosciences Announces Positive Topline Data With Superior Outcomes From a Randomized Head-to-Head Study of Ibi324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2602059319","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602059319?lang=en_us&edition=fundamental","pubTime":"2026-01-09 08:00","pubTimestamp":1767916800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA3RXW3C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU2097828714.EUR","HK0000165453.HKD","LU2328871848.SGD","BK1583","LU2242644610.SGD","LU1969619763.USD","LU2097828631.EUR","LU0502904849.HKD","LU2097828557.USD","LU2097828474.EUR","LU2488822045.USD","LU2097828805.USD","01801","LU0455707207.USD","BK1589"],"gpt_icon":0},{"id":"1117324679","title":"JPMorgan Increases Stake in Innovent Biologics (01801) by Approximately 3.17 Million Shares at HK$78.45 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1117324679","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117324679?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:31","pubTimestamp":1767871863,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on January 2nd, JPMorgan increased its holding in Innovent Biologics (01801) by 3,173,036 shares. The transaction was executed at a...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJTD4N35.SGD","LU1280957306.USD","LU0320765489.SGD","LU2097828631.EUR","LU0310799852.SGD","LU1084165304.USD","IE00B1BXHZ80.USD","LU1162221912.USD","LU1551013425.SGD","LU1363072403.SGD","LU2236285917.USD","IE00BZ1G4Q59.USD","LU0320765646.SGD","LU0683600562.USD","LU0502904849.HKD","LU0265550359.USD","LU1244550494.USD","LU2462157665.USD","IE0034235188.USD","IE00BKDWB100.SGD","IE000M9KFDE8.USD","IE00BLSP4239.USD","BK1161","LU1969619763.USD","BK4534","LU2242644610.SGD","LU0070302665.USD","LU1629891620.HKD","LU1267930490.SGD","LU1496350502.SGD","LU1914381329.SGD","LU2552382215.SGD","LU2237443382.USD","IE00BFXG1179.USD","LU1668664300.SGD","LU0345769631.USD","LU0048584097.USD","LU2213496289.HKD","LU0496365809.HKD","BK4504","LU0964807845.USD","LU2023250843.SGD","LU2237443895.HKD","LU0455707207.USD","LU0417517546.SGD","LU2552382058.USD","LU0345770308.USD","LU2430703251.USD","LU0820561909.HKD","LU1116320901.HKD","BK4588","HK0000165453.HKD","LU1974910355.USD","LU1917777945.USD","LU0106831901.USD","LU1064131342.USD","IE00BJLML261.HKD","LU0006306889.USD","LU0820561818.USD","LU1366192091.USD","LU2242649171.HKD","LU2097828805.USD","LU1720051108.HKD","BK4516","LU2264538146.SGD","LU0211331839.USD","LU2097828474.EUR","LU0976567544.SGD","LU2381873111.SGD","LU2456880835.USD","LU2756315664.SGD","LU0256863811.USD","BK4550","LU2592432038.USD","LU0170899867.USD","BK4566","LU0942090050.USD","SG9999002232.USD","LU2237443549.SGD","IE00BJTD4V19.USD","IE00BHPRN162.USD","LU2417539215.USD","IE00BLSP4452.SGD","LU1988902786.USD","LU1119994496.HKD","BK1589","SG9999002224.SGD","LU0215105999.USD","LU0345769128.USD","LU2237443978.SGD","IE00BDRTCR15.USD","IE00BYXW3230.USD","LU1670628061.USD","LU2328871848.SGD","LU2097828714.EUR","LU2430703095.HKD","LU2746668461.USD","LU2054465674.USD","LU2505996681.GBP","LU0208291251.USD","LU2097828557.USD","LU0689472784.USD","IE00B3S45H60.SGD","LU0211327993.USD","LU1670627923.USD","LU2106854487.HKD","LU1032466523.USD","LU1894683348.USD","LU2023250504.SGD","LU1244550577.SGD","BK4533","LU1261432733.SGD","LU2357305700.SGD","LU0943347566.SGD","LU2505996509.AUD","LU2552382132.HKD","IE0034235303.USD","LU0203345920.USD","LU2237443622.USD","LU0323591593.USD","BK4585","IE00B775SV38.USD","LU0211326839.USD","LU1496350171.SGD","LU1116320737.USD","IE00BN8TJ469.HKD","IE00BKVL7J92.USD","LU0868494617.USD","IE00BWXC8680.SGD","LU0211326755.USD","LU0971096721.USD","LU1720051017.SGD","LU2746668974.SGD","LU0787776722.HKD","LU0868494708.USD","LU0640476718.USD","IE00B1XK9C88.USD","LU2756315318.SGD","BK4581","LU0234572021.USD","LU1548497426.USD","LU0820562030.AUD","LU0211328371.USD","LU0238689110.USD","LU0267386448.USD","JPM","01801","LU0203347892.USD","IE00BBT3K403.USD","LU0882574139.USD","LU1551013342.USD","LU1894683264.USD","LU2430703178.SGD","LU0251132253.USD","LU0106261372.USD","IE00BDCRKT87.USD","LU2488822045.USD","BK1583","LU2237443465.HKD","LU0149725797.USD","LU1145028129.USD","LU0345770993.USD","LU2211815571.USD","LU1244550221.USD","IE0034235295.USD","LU0265550946.USD","BK4207","LU2023250330.USD"],"gpt_icon":0},{"id":"2601898608","title":"Innovent Should Hold Own in Weight-Loss Drug Race Despite Intensifying Competition -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2601898608","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601898608?lang=en_us&edition=fundamental","pubTime":"2026-01-06 17:24","pubTimestamp":1767691440,"startTime":"0","endTime":"0","summary":"0924 GMT - Innovent should hold its ground in the GLP-1 weight-loss drug segment despite intensifying market competition, Nomura analyst Jialin Zhang says in a note. He notes pharma majors Eli Lilly and Novo Nordisk both cut prices of their GLP-1 products in China. However, Zhang remains confident in Innovent's execution capability, noting the higher price point and differentiated mechanism of its GLP-1 treatment, mazdutide, allow the company to distinguish itself. While many Chinese drugmakers lack experience marketing quasi-over-the-counter drugs, Zhang expects Innovent to benefit from a first-mover advantage in scaling sales, which will support growth in 2026 and beyond. Nomura maintains a buy rating and HK$105.80 target price on the stock, which last closed at HK$84.50. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","BK1589","HK0000165453.HKD","LU2097828474.EUR","LU2097828714.EUR","LU2328871848.SGD","BK1161","LU0455707207.USD","LU0502904849.HKD","LU2097828557.USD","LU2488822045.USD","BK1583","LU2242644610.SGD","LU2097828805.USD","01801","LU2097828631.EUR"],"gpt_icon":0},{"id":"2595171739","title":"Novo and Lilly cut prices of weight-loss drugs in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2595171739","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595171739?lang=en_us&edition=fundamental","pubTime":"2025-12-29 23:39","pubTimestamp":1767022786,"startTime":"0","endTime":"0","summary":"UPDATE 2-Novo and Lilly cut prices of weight-loss drugs in ChinaRecasts with Eli Lilly's price cut in paragraphs 6-8","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nL1N3XZ0B7:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","LU0128522157.USD","LU0234572021.USD","LU1328277881.USD","LU1989771016.USD","LU0417517546.SGD","LU0588545730.USD","LU2168564222.USD","LU0061475181.USD","LU0823416689.USD","BK1591","LU0244354667.USD","LU1102505929.USD","LU2168563687.JPY","LU2237443895.HKD","LU2168564495.EUR","SG9999002828.SGD","01093","LU0856984785.SGD","LU0432979614.USD","01801","IE00BFTCPJ56.SGD","IE0008368742.USD","HMTD.SI","LU0006306889.USD","LU2471134523.USD","LU0572944931.SGD","LU1675838814.USD","SG9999014914.USD","IE00B3M56506.USD","METmain","LU0109391861.USD","LU2552382215.SGD","IE00B031HY20.USD","LU0823039010.USD","LU0315178854.USD","LU0455707207.USD","LU1813983027.USD","LU1188198961.HKD","BK1615","LU0823038988.USD","LU1152091168.USD","LLY","IE00BFSS8Q28.SGD","02566","LU0051755006.USD","LU1323998911.USD","LU1688375341.USD"],"gpt_icon":1},{"id":"1173862941","title":"INNOVENT BIO (01801): TYVYT® (Ipilimumab N01 Injection) Approved by NMPA for Combined Use with Sintilimab in Neoadjuvant Treatment of Colon Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1173862941","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173862941?lang=en_us&edition=fundamental","pubTime":"2025-12-29 07:40","pubTimestamp":1766965218,"startTime":"0","endTime":"0","summary":"INNOVENT BIO (01801) announced that TYVYT® (Ipilimumab N01 Injection, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody, R&D code: IBI310) has received approval for marketing...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU0455707207.USD","BK1589","LU2242644610.SGD","LU1969619763.USD","LU2097828631.EUR","LU0502904849.HKD","LU2488822045.USD","LU2097828714.EUR","LU2097828805.USD","01801","LU2097828474.EUR","HK0000165453.HKD","BK1161","LU2328871848.SGD","LU2097828557.USD"],"gpt_icon":0},{"id":"2595749572","title":"Innovent Biologics - Tabosun Receives Nmpa Approval for Colon Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2595749572","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595749572?lang=en_us&edition=fundamental","pubTime":"2025-12-29 07:30","pubTimestamp":1766964645,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251228:nFWN3XW048:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","LU0455707207.USD","BK1589","LU2242644610.SGD","LU1969619763.USD","LU2097828631.EUR","LU0502904849.HKD","LU2488822045.USD","LU2097828714.EUR","LU2097828805.USD","01801","LU2097828474.EUR","HK0000165453.HKD","BK1161","LU2328871848.SGD","LU2097828557.USD"],"gpt_icon":0},{"id":"2595274950","title":"Innovent Biologics Gains China Approval for TABOSUN and Sintilimab in Colon Cancer Neoadjuvant Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2595274950","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595274950?lang=en_us&edition=fundamental","pubTime":"2025-12-29 07:30","pubTimestamp":1766964633,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. announced that China's National Medical Products Administration has approved the New Drug Application for TABOSUN  in combination with sintilimab as a neoadjuvant treatment for stage IIB-III resectable microsatellite instability-high  or mismatch repair deficient colon cancer. The approval is based on interim analysis from the NeoShot trial, which showed a pathological complete response rate of 82% among the first 50 patients treated, without significant safety risks compared to direct surgery.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251228:nNDL2f1t1D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU0502904849.HKD","BK1583","LU0455707207.USD","LU1969619763.USD","LU2097828557.USD","LU2097828631.EUR","LU2097828805.USD","LU2488822045.USD","LU2097828474.EUR","LU2328871848.SGD","01911","LU2097828714.EUR","LU2242644610.SGD","BK1589","BK1161","HK0000165453.HKD","BK1147"],"gpt_icon":0},{"id":"2594233216","title":"Innovent Biologics Wins NMPA Approval for First Domestic CTLA-4 Antibody TABOSUN in Colon Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2594233216","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594233216?lang=en_us&edition=fundamental","pubTime":"2025-12-25 16:45","pubTimestamp":1766652331,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has received regulatory approval from China's National Medical Products Administration  for TABOSUN , the first domestic cytotoxic lymphocyte-associated antigen-4  monoclonal antibody. The approval is for use in combination with TYVYT  as a neoadjuvant treatment for patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient  colon cancer. This dual-immunotherapy regimen is the first and only approved globally for neoadjuvant treatment of colon cancer, addressing a significant unmet clinical need and offering a new therapeutic option for patients in China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251225:nNDL681Kfl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1147","HK0000165453.HKD","LU2097828714.EUR","LU2328871848.SGD","BK1583","LU2242644610.SGD","01911","LU1969619763.USD","LU2097828631.EUR","LU0502904849.HKD","LU2097828557.USD","LU2097828474.EUR","LU2488822045.USD","LU2097828805.USD","01801","LU0455707207.USD","BK1589"],"gpt_icon":0},{"id":"1151207812","title":"Innovent Biologics (01801) Shareholder Deposits Shares with HSBC Hong Kong, Valued at HK$4.598 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1151207812","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151207812?lang=en_us&edition=fundamental","pubTime":"2025-12-25 08:14","pubTimestamp":1766621658,"startTime":"0","endTime":"0","summary":"Latest data from the Hong Kong Stock Exchange reveals that on December 24, a shareholder of Innovent Biologics (01801) deposited shares with HSBC Hong Kong, with a custody market value of HK$4.598...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","LU0516422952.EUR","BK1161","LU0310800965.SGD","LU0417516738.SGD","HSBA.UK","01801","LU0516423091.SGD","BK4207","HSBC","LU0149721374.USD","LU1969619763.USD","LU2328871848.SGD","LU2488822045.USD","HK0000165453.HKD","BK1589","LU2097828805.USD","LU0516423174.USD","HSHD.SI","BK1610","LU0164880469.USD","LU0502904849.HKD","LU2097828557.USD","BK4585","LU2097828474.EUR","LU1267930227.SGD","BK4521","LU1481107354.HKD","LU0516422440.USD","03143","BK1601","BK1583","BK4588","LU0348735423.USD","LU0128525689.USD","LU0052756011.USD","LU0455707207.USD","LU2236285917.USD","LU0540923850.HKD","LU0516422366.SGD","BK1572","00005","LU2097828631.EUR","LU2242644610.SGD","LU0634319403.HKD","BK1231"],"gpt_icon":0},{"id":"1163646631","title":"Shanghai Government and Enterprise Collaborate to Forge New Compliance Model","url":"https://stock-news.laohu8.com/highlight/detail?id=1163646631","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163646631?lang=en_us&edition=fundamental","pubTime":"2025-12-25 05:50","pubTimestamp":1766613025,"startTime":"0","endTime":"0","summary":"To further enhance the standardized operations and risk management of pharmaceutical companies and support the innovative development of the biopharmaceutical industry, the Shanghai Market Regulation...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1161","LU2097828805.USD","LU2097828557.USD","LU2242644610.SGD","01801","LU2328871848.SGD","BK1583","LU2097828714.EUR","HK0000165453.HKD","LU2097828474.EUR","LU0455707207.USD","LU2488822045.USD","LU0502904849.HKD","LU2097828631.EUR","LU1969619763.USD"],"gpt_icon":0},{"id":"1161261107","title":"Southbound Capital Flow Statistics (T+2) for Dec 23","url":"https://stock-news.laohu8.com/highlight/detail?id=1161261107","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161261107?lang=en_us&edition=fundamental","pubTime":"2025-12-23 07:39","pubTimestamp":1766446787,"startTime":"0","endTime":"0","summary":"On December 18, Xiaomi Group-W (01810), Meituan-W (03690), and Yangtze Optical Fibre and Cable (06869) ranked as the top three stocks by net southbound capital inflow, with inflows of HK$904 million,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708995153.HKD","LU1282651048.USD","LU2242644610.SGD","BK1185","03990","LU0589944569.HKD","LU0572944931.SGD","LU0231459107.USD","LU1115378108.SGD","IE0003851619.USD","BK1528","LU0287142896.SGD","LU1993786604.SGD","LU1734074674.USD","IE0031814852.USD","03145","LU1188198961.HKD","SG9999004220.SGD","LU1880398471.USD","LU0054450605.USD","BK1190","LU1497733557.USD","LU1522347837.USD","LU0117841782.USD","SG9999010052.SGD","LU0049853897.USD","IE0008369823.USD","LU1719994722.HKD","LU1242518931.SGD","LU0608807946.USD","SUHJY","LU1048588211.SGD","LU0061477393.USD","IE0008368304.USD","SG9999006597.SGD","LU0955648018.USD","LU0502904849.HKD","SG9999001903.USD","LU2088748376.SGD","09985","IE00BMPRXR70.SGD","LU0278937759.USD","LU0516422952.EUR","LU2088747725.USD","IE00B543WZ88.USD","LU2226246903.HKD","LU0819121731.USD","BK1608","LU0370786039.SGD","LU2348774022.SGD","LU0516422366.SGD","IE00BSPPW651.USD","LU2097828557.USD","LU0882747503.HKD","BK1588","LU0541501648.USD","LU0048597586.USD","LU0106252389.USD","BK1587","LU0594300179.USD","BK1544","LU0455707207.USD","LU0054237671.USD","01347","LU0384037296.USD","HK0000252152.HKD","LU0577902454.USD","LU0878005551.USD","03121","SGXZ90724238.SGD","BK1240","LU0251144936.SGD","LU0648000940.SGD","LU0235996351.USD","LU0823041008.USD","LU0314109678.HKD","SG9999002562.SGD","LU0516423091.SGD","BK1614","LU0405327148.USD","LU0163747925.USD","LU1508157978.USD","BK1152","LU1224444064.USD","09988","01686","LU0501845795.SGD","BK1569","IE00BF5LJ272.USD","LU0345780521.USD","LU0431992006.USD","LU0540923850.HKD","LU0214875030.USD","LU1868837722.USD","BK1521","BK1154","LU1064130708.USD","LU1770036033.HKD","LU0359201885.HKD","LU0345776255.USD","LU0348816934.USD","LU0873338254.USD","HXXD.SI","BK1142","LU1242518857.USD","LU0821914370.USD","LU0266512127.USD","LU0828238088.HKD","LU1044874839.SGD","LU1046422090.SGD","BK1618","LU0348735423.USD","LU1366334651.USD","LU2045819591.USD","LU1481107354.HKD","BK1542","BK1231","LU1251922891.USD","00003","IE00B29SXG58.USD","LU0029874905.USD","BK1184","LU1497734951.SGD","HPAD.SI","LU1328277881.USD","LU0608807433.USD","IE00BZ08YR35.GBP","LU1105468828.SGD","LU2449936058.SGD","LU0737861772.HKD","LU0856984785.SGD","LU1956131251.USD","LU2399975544.HKD","LU0315178854.USD","01810","IE00BVYPNQ40.USD","IE00BKZH1Z71.USD","BK1584","02800","LU0106959298.USD","01117","LU0648948544.HKD","MPNGY","LU0477156797.USD","LU1720051108.HKD","HK0000500386.USD","89988","LU2088748020.USD","LU0823413660.USD","LU0228367735.SGD","601318","BK1560","LU0051755006.USD","LU2125910500.SGD","SG9999006514.SGD","SG9999003461.SGD","BK1507","02328","LU0633140727.USD","SG9999009997.SGD","BK1515","01952","LU0831103253.SGD","LU0164880469.USD","LU1515016050.SGD","00386","LU0672654166.SGD","LU0955623706.USD","LU0328353924.USD","02899","IE00B3T34201.USD","LU2226123227.USD","LU0345775950.USD","LU0543330483.HKD","LU0047713382.USD","LU2125910849.SGD","LU1634259391.SGD","LU0577902298.EUR","LU1008478684.HKD","BK1149","LU2152927971.USD","LU2097828474.EUR","LU0197773160.USD","00107","03143","00388","LU0052750758.USD","LU1152091168.USD","LU0588545730.USD","00363","HK0000320223.HKD","LU0130103400.USD","BK1127","80883","HBBD.SI","LU0577902611.USD","BK1229","BK1594","LU0577902371.SGD","LU0229494975.USD","LU1960683339.HKD","LU0048388663.USD","LU0359202008.SGD","LU1880383440.USD","LU0259732245.USD","BK1221","BK1505","HK0000252160.HKD","XIACY","LU0293314216.USD","LU1366334578.USD","LU0043850808.USD","BK1506","LU0348827113.USD","BK1555","82318","LU0143863784.USD","LU0918141705.HKD","LU2257852520.SGD","LU0823426308.USD","LU0823039010.USD","IE00BWDBJ730.SGD","BK1610","LU0588546209.SGD","LU0072913022.USD","LU2088748293.HKD","BK1550","06160","LU0197773673.USD","IE00BMCWC346.EUR","LU0266512473.USD","00941","LU0348783662.USD","PNGAY","LU0488056044.USD","SG9999000327.SGD","LU0128522157.USD","LU0640798160.USD","LU0823038988.USD","LU0708995583.HKD","LU0165289439.USD","LU1235295612.USD","BK1206","00016","81810","LU1439103000.SGD","LU0823397285.USD","BK1583","LU0320764599.SGD","LU0823413587.USD","LU0084288322.USD","LU1102505929.USD","IE0032431581.USD","LU2097829019.USD","BK1523","BK1554","LU1130305938.SGD","LU1282649141.HKD","LU1224709979.USD","BK1237","IE00BZ08YT58.USD","LU0117844026.USD","LU0348825331.USD","LU1655091459.SGD","BK1099","LU0231483743.USD","LU0348788117.USD","BK1161","BK1615","LU0106259558.USD","IE00BMPRXN33.USD","LU0541502299.USD","LU1961090484.USD","LU0261947096.USD","LU0143863198.USD","HKXCY","IE0003795394.USD","LU0499858602.USD","LU0029875118.USD","LU1316542783.SGD","BK1128","00857","LU0449509016.USD","BK1565","LU0096374516.USD","LU1051768304.USD","BK1193","03868","IE00B1G9TM23.USD","02318","LU0791591158.USD","LU0762541174.USD","LU0642271901.SGD","LU0572939691.SGD","LU0955669360.SGD","LU0307460666.USD","LU0320764243.SGD","LU0630378692.HKD","LU0577902538.SGD","SG9999010078.USD","HK0000306685.HKD","LU2488822045.USD","LU1152091754.HKD","LU3063872942.SGD","LU2097828631.EUR","BK1131","06098","LU0149721374.USD","LU0196878994.USD","LU0593848301.USD","BK1258","LU0210526637.USD","LU0634319403.HKD","LU0828237510.HKD","BK1198","80388","LU0650527681.SGD","LU0737861699.HKD","LU1720051017.SGD","IE00BPRC5H50.USD","IE0034224299.USD","LU0871576103.HKD","LU0633140560.USD","HEXmain","BK1536","LU2088747998.USD","BK1191","LU0762542818.HKD","LU1794554557.SGD","HK0000320264.USD","LU0229945570.USD","LU1769817096.USD","09899","BK1562","BK1249","LU0132412106.USD","LU1048596156.SGD","BK1591","LU2476274720.SGD","LU0244354667.USD","LU0700851271.USD","LU1497733631.SGD","LU0211977185.USD","IE00B19Z5X02.USD","LU1044876610.USD","LU1969619763.USD","LU0588545904.SGD","BK1517","HMTD.SI","SG9999002463.SGD","LU0823397103.USD","01093","03442","LU0417516571.SGD","03037","LU0169518387.USD","LU1675838814.USD","BK1575","LU0516423174.USD","LU0315179316.USD","IE00B0JY6N72.USD","BK1216","LU0348783233.USD","LU0228659784.USD","LU1634259557.SGD","LU0449515922.USD","LU0417516902.SGD","LU1831875114.USD","LU1813983027.USD","LU0531971595.HKD","LU0683595622.HKD","SG9999001689.USD","LU0469268626.HKD","LU0828237940.HKD","LU2097828714.EUR","LU0405327494.USD","LU1770034418.SGD","LU0261950983.USD","LU2153592121.USD","LU1023057109.AUD","00272","BK1500","LU0561508036.HKD","LU0210527791.USD","LU1226287792.SGD","LU0531970944.HKD","LU0164865239.USD","LU0164872284.USD","LU0880133367.SGD","LU0326948709.USD","SG9999001226.SGD","LU1568876251.USD","IE00BQJZWZ67.USD","BK1501","LU1720050803.USD","IE00B031HY20.USD","LU0605514214.HKD","LU0320764755.SGD","06869","LU1226287529.USD","LU0128522744.USD","LU0181495838.USD","BK1607","LU0543330566.HKD","HK0000306701.USD","BK1567","LU1048484197.HKD","HK0000165453.HKD","PAImain","LU2476274308.USD","LU1810669033.SGD","LU0039217434.USD","LU1323998911.USD","LU0890818403.SGD","LU0588545490.SGD","LU0611395673.USD","LU1102505762.USD","SG9999014674.SGD","BK1577","LU0868486357.SGD","LU0762540952.USD","LU0067412154.USD","LU0130518102.USD","LU0499858438.USD","LU0345780281.USD","LU1226288253.USD","BK1212","LU0886674414.USD","LU2293587155.HKD","LU0348805143.USD","LU0254981946.USD","BK1134","LU2357305700.SGD","01801","LU1868838027.USD","LU1051769294.HKD","BK1553","LU1568876335.HKD","LU0456827905.SGD","LU0797268264.HKD","IE00BZ08YS42.EUR","03328","IE0009570106.USD","LU2097828805.USD","LU0594300419.USD","LU2039709279.SGD","LU0326950275.SGD","LU0516422440.USD","LU1868837565.USD","LU1951186391.HKD","BK1502","LU0878004406.USD","LU0441854154.USD","LU0417516738.SGD","03167","LU1044875133.USD","LU1769817179.HKD","BK1586","ALBmain","LU0819123356.HKD","LU0329678337.USD","IE0003895053.USD","IE00B031J352.USD","LU1282651121.HKD","BK1148","BK1574","BK1527","LU1880398554.USD","IE00BYV24P56.USD","LU1196710864.SGD","LU0607220059.USD","01258","LU0348784397.USD","BK1233","LU1303224171.USD","LU0862451753.SGD","LU1688375341.USD","LU1226287875.USD","BK1226","LU1282649067.USD","LU0979878070.USD","LU0149534421.HKD","LU0784639295.USD","LU1880383366.USD","LU1642822792.SGD","IE00BVYPNP33.GBP","IE00B0169N27.USD","BK1230","LU0865486749.SGD","LU0651946864.USD","LU1282648689.USD","LU0509642566.USD","SG9999002828.SGD","LU1064131003.USD","BK1559","LU0572940350.SGD","LU0264606111.USD","LU1548497426.USD","SG9999000459.SGD","LU0651947912.USD","03968","SG9999001093.SGD","80016","LU0127658192.USD","IE00BGHQDM52.EUR","LU2148510915.USD","LU1981816686.USD","LU0269904917.USD","LU0831093199.SGD","LU0049112450.USD","BK1604","LU0456854461.SGD","LU0048580855.USD","BK1589","IE00B1G9TL16.USD","LU0823040885.USD","LU0329678170.USD","LU1282649810.SGD","LU1328615791.USD","LU0630378429.USD","LU0675040207.SGD","LU0791590937.USD","LU0072462343.USD","LU0898667661.SGD","LU0396098781.USD","LU1201861165.SGD","LU1226288170.HKD","LU2226123490.SGD","IE0008368742.USD","SG9999001051.SGD","LU2778985437.USD","03690","LU0173614495.USD","BABA","LU0359201612.USD","BK1163","LU0918141887.USD","IE00B5MMRT66.SGD","LU1808992512.USD","LU1316543674.SGD","LU0862451837.USD","LU1807302812.USD","LU1211504680.USD","SG9999001846.SGD","LU0463099449.HKD","IE00B3M56506.USD","LU0140636845.USD","01186","BK1592","LU2328871848.SGD","LU0348814723.USD","BK1601","LU0823426480.USD","LU0327786744.USD","00006","LU0456846285.SGD","01288","LU2087589342.USD","LU0011963245.USD","LU1504937902.USD","LU2663582299.SGD"],"gpt_icon":1},{"id":"1122364808","title":"Hong Kong Market Insights: Hainan Free Trade Port Closure Holds Major Significance; Autonomous Driving Sector Sees Intensive Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=1122364808","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122364808?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:21","pubTimestamp":1766150506,"startTime":"0","endTime":"0","summary":"【Market Overview】   The market showed signs of vitality today, unlike the sluggish performance in recent days, with both mainland and Hong Kong markets advancing steadily. The Hang Seng Index closed...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"85e8aafb51ba0ad706197d405ff70b96","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1794554557.SGD","LU2242644610.SGD","02269","BK1147","BK1183","02431","HK0000165453.HKD","02533","BK1207","LU0516422366.SGD","LU1969619763.USD","09880","BK1583","LU2039709279.SGD","LU0417516902.SGD","LU0359201885.HKD","LU1688375341.USD","LU0456827905.SGD","LU0979878070.USD","LU0227179875.USD","LU0588546209.SGD","06821","00699","03908","LU1251922891.USD","LU1023057109.AUD","LU1770034418.SGD","LU0348767384.USD","01316","BK1587","LU0455707207.USD","LU2328871848.SGD","09660","LU0348825331.USD","BK1501","BK1507","LU0327786744.USD","BK1610","BK1500","LU0516423091.SGD","LU3063872942.SGD","LU0593848301.USD","BK1115","09863","BK1163","LU0516423174.USD","LU1880383366.USD","LU2488822045.USD","LU0819121731.USD","01801","LU0140636845.USD","BK1191","01318","BK1613","BK1521","BK0276","LU0359202008.SGD","LU0502904849.HKD","LU1303224171.USD","LU0320764599.SGD","LU0359201612.USD","BK1179","BK1224","BK1516","BK1564","LU0181495838.USD","LU0516422440.USD","LU0417516738.SGD","LU0823426308.USD","LU0039217434.USD","01999","SG9999002828.SGD","LU2097828714.EUR","LU2663582299.SGD","LU2097828631.EUR","LU0708995583.HKD","02039","LU0052750758.USD","BK1575","LU1719994722.HKD","BK1509","02498","LU0348735423.USD","02050","BK1141","BK1588","601995","LU0043850808.USD","BK1539","SG9999002562.SGD","06160","BK1144","LU2097828474.EUR","LU1720050803.USD","LU0572944931.SGD","LU1508157978.USD","LU1242518931.SGD","01880","BK1119","BK1109","IE00B0JY6N72.USD","01057","LU0456846285.SGD","LU1242518857.USD","LU0051755006.USD","LU0823426480.USD","LU0307460666.USD","LU0348766576.USD","LU2097828557.USD","BK1576","BK1589","09868","03759","LU0326950275.SGD","LU2097828805.USD","LU1781817850.SGD","LU1580142542.USD","SG9999002463.SGD","BK1161","LU0856984785.SGD","LU0516422952.EUR"],"gpt_icon":1},{"id":"2592193343","title":"Innovent Biologics (SEHK:1801): Reassessing Valuation After Landmark Nature Phase 3 Mazdutide Publications","url":"https://stock-news.laohu8.com/highlight/detail?id=2592193343","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592193343?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:18","pubTimestamp":1766150313,"startTime":"0","endTime":"0","summary":"Innovent Biologics (SEHK:1801) just hit a scientific milestone, with two Phase 3 trials of its dual GCG/GLP-1 drug mazdutide published back to back in Nature, sharpening the investment case around its diabetes franchise.\nSee our latest analysis for Innovent Biologics.\nThe latest Nature publications cap a run of positive catalysts, including NRDL additions and Hang Seng index inclusion. This comes even as the 30 day share price return of minus 7.1% contrasts with a powerful 1 year total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-reassessing-valuation-after-land","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-reassessing-valuation-after-land","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2242644610.SGD","LU0502904849.HKD","LU2097828474.EUR","DCF","LU1969619763.USD","LU2097828714.EUR","BK1583","LARK","01801","LU2097828557.USD","BK4211","LU2328871848.SGD","LU2097828805.USD","LU2488822045.USD","BK1161","LU0455707207.USD","BK1589","HK0000165453.HKD","LU2097828631.EUR"],"gpt_icon":0},{"id":"1181976896","title":"Zhitong HK Morning Briefing | State Council Issues Guidelines on Combating Tobacco-Related Illegal Activities; Overnight US Stocks Rise Across the Board","url":"https://stock-news.laohu8.com/highlight/detail?id=1181976896","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181976896?lang=en_us&edition=fundamental","pubTime":"2025-12-19 07:37","pubTimestamp":1766101047,"startTime":"0","endTime":"0","summary":"**Top Headline**   Two studies published on *Nature*'s website confirm the efficacy and safety of a new diabetes drug developed jointly by Chinese and US pharmaceutical companies. The research,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2152927971.USD","IE0008368742.USD","LU0043850808.USD","LU1048588211.SGD","LU0117841782.USD","LU2257852520.SGD","LU0456846285.SGD","BK1119","LU0228659784.USD","IE00BPRC5H50.USD","LU0868486357.SGD","LU0455707207.USD","LU0251144936.SGD","LU0594300419.USD","LU1880383440.USD","LU2476274308.USD","LU0261950983.USD","LU2242644610.SGD","LU2097828805.USD","BK1604","LU0047713382.USD","LU1064130708.USD","BK1594","LU0164939612.USD","LU0683595622.HKD","LU0572944931.SGD","LU1102505929.USD","LU1794554557.SGD","LU0509642566.USD","LU0878005551.USD","LU0577902538.SGD","LU0082770016.SGD","BK1539","LU1328277881.USD","LU1251922891.USD","LU0370786039.SGD","LU0196878994.USD","LU0531971595.HKD","LU0588545730.USD","LU0214875030.USD","LU0823039010.USD","LU1105468828.SGD","LU2328871848.SGD","LU2488822045.USD","LU2097828557.USD","LU1688375341.USD","IE00B0JY6N72.USD","LU1226287529.USD","LU1770036033.HKD","LU2097828631.EUR","LU1734074674.USD","LU1023057109.AUD","LU1152091754.HKD","LU2039709279.SGD","LU1323998911.USD","IE0032431581.USD","LU0054237671.USD","LU0856984785.SGD","LU0871576103.HKD","BK1181","03393","LU0611395673.USD","BK1591","LU0588546209.SGD","LU0588545490.SGD","LU0700851271.USD","LU2226246903.HKD","LU0052750758.USD","LU0797268264.HKD","IE00B543WZ88.USD","LU1868837722.USD","SG9999002463.SGD","LU0164865239.USD","LU0823040885.USD","BK1142","LU1242518857.USD","LU0164880469.USD","LU0499858602.USD","BK1615","BK1161","LU0084288322.USD","LU0541501648.USD","LU0149721374.USD","LU0594300179.USD","LU0620787316.HKD","LU0128522157.USD","SG9999001689.USD","LU0577902454.USD","LU0821914370.USD","LU0865486749.SGD","LU0449509016.USD","LU1675838814.USD","LU0348816934.USD","LU0029875118.USD","LU0359201885.HKD","LU1282648689.USD","LU0320764755.SGD","LU0327786744.USD","LU0880133367.SGD","LU0502904849.HKD","LU2097828474.EUR","LU1993786604.SGD","LU0067412154.USD","LU0173614495.USD","LU0593848301.USD","LU1008478684.HKD","LU0672654166.SGD","BK1209","BK1589","LU0106252389.USD","LU0463099449.HKD","LU0499858438.USD","06055","LU0048580855.USD","LU0049853897.USD","LU2087589342.USD","SG9999002828.SGD","IE0008369823.USD","LU0417516902.SGD","LU0577902611.USD","LU1328615791.USD","BK1583","LU0345776255.USD","CNHmain","BK1618","LU1242518931.SGD","LU1868838027.USD","LU1960683339.HKD","LU2148510915.USD","LU0541502299.USD","LU0359202008.SGD","CYB","LU0823041008.USD","LU1880383366.USD","LU0072462343.USD","SG9999000459.SGD","SG9999002562.SGD","LU0315178854.USD","LU1188198961.HKD","LU1969619763.USD","HK0000165453.HKD","LU0132412106.USD","BK1554","LU0072913022.USD","LU0011963245.USD","LU0708995583.HKD","LU0326950275.SGD","LU1102505762.USD","LU2778985437.USD","BK1179","LU0577902371.SGD","LU1770034418.SGD","BK1509","LU0348805143.USD","LU0348827113.USD","LU2399975544.HKD","LU0269904917.USD","LU0348825331.USD","LU0873338254.USD","LU0211977185.USD","LU0540923850.HKD","LU2045819591.USD","LU0650527681.SGD","BK1521","LU0543330483.HKD","MPNGY","LU1064131003.USD","SG9999014674.SGD","LU0164872284.USD","LU0417516738.SGD","LU0737861699.HKD","SG9999000327.SGD","LU0307460666.USD","LU0561508036.HKD","LU0359201612.USD","LU0828237510.HKD","BK1610","LU0143863198.USD","LU2476274720.SGD","HGmain","LU0918141705.HKD","LU1808992512.USD","IE0034224299.USD","LU0588545904.SGD","BK1575","LU0348814723.USD","LU1720050803.USD","LU1807302812.USD","LU0633140560.USD","LU0314109678.HKD","IE00B29SXG58.USD","LU0082770016.USD","IE00B3M56506.USD","LU0326948709.USD","LU0819121731.USD","LU1224709979.USD","LU1719994722.HKD","LU2125910500.SGD","IE00BF5LJ272.USD","LU1831875114.USD","LU0634319403.HKD","BK1580","METmain","LU0231483743.USD","LU1813983027.USD","LU0287142896.SGD","LU0320764599.SGD","BK1148","LU0633140727.USD","LU1303224171.USD","LU0828238088.HKD","LU0823426480.USD","LU0605514214.HKD","LU1048596156.SGD","LU1868837565.USD","BK1598","LU0039217434.USD","LU0348735423.USD","SG9999001903.USD","HMTD.SI","LU2097828714.EUR","LU0143863784.USD","LU1961090484.USD","LU1152091168.USD","UCmain","LU0828237940.HKD","LU1481107354.HKD","IE00B031HY20.USD","BK1233","LU0501845795.SGD","LU0819123356.HKD","LU0348788117.USD","IE00B5MMRT66.SGD","LU0244354667.USD","LU0140636845.USD","LU0823038988.USD","LU0979878070.USD","LU0054450605.USD","LU0918141887.USD","LU0823426308.USD","LU0449515922.USD","LU0051755006.USD","LU0048597586.USD","LU0210526637.USD","LU0181495838.USD","LU0456827905.SGD","LU0589944569.HKD","LU0431992006.USD","LU0577902298.EUR","01801","LU0345775950.USD","LU0165289439.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0361},{"period":"1month","weight":-0.0013},{"period":"3month","weight":-0.0938},{"period":"6month","weight":-0.1973},{"period":"1year","weight":1.3812},{"period":"ytd","weight":0.0321}],"compareEarnings":[{"period":"1week","weight":0.0004},{"period":"1month","weight":0.0166},{"period":"3month","weight":0.0317},{"period":"6month","weight":0.0749},{"period":"1year","weight":0.3239},{"period":"ytd","weight":0.0447}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.625,"avgChangeRate":0.100662},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.021767},{"month":4,"riseRate":0.714286,"avgChangeRate":0.040816},{"month":5,"riseRate":0.428571,"avgChangeRate":0.027398},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"INNOVENT BIO","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INNOVENT BIO,01801,INNOVENT BIO股票,INNOVENT BIO股票老虎,INNOVENT BIO股票老虎国际,INNOVENT BIO行情,INNOVENT BIO股票行情,INNOVENT BIO股价,INNOVENT BIO股市,INNOVENT BIO股票价格,INNOVENT BIO股票交易,INNOVENT BIO股票购买,INNOVENT BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}